Pegsunercept
| Clinical data | |
|---|---|
| Routes of administration | subcutaneous injection |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number |
330988-75-5  |
| ChemSpider | none |
| UNII |
Q5I7SFZ853  |
| KEGG |
D05393 |
| Chemical and physical data | |
| Formula | C502H758N154O165S16 |
| Molar mass | 12,103 g/mol (protein part) |
| (what is this?) (verify) | |
Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.
Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]
References
- ↑ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
- 1 2 Furst, D.; Fleischmann, R.; Kopp, E.; Schiff, M.; Edwards C, 3.; Solinger, A.; Macri, M.; 990136 Study, G. (2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of rheumatology. 32 (12): 2303–2310. PMID 16331754.
This article is issued from Wikipedia - version of the 10/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.